Arbutus announces decision to discontinue development of ab-506, an oral capsid inhibitor for the treatment of chronic hepatitis b

Arbutus biopharma corporation announced its decision to discontinue the clinical development of ab-506, an oral capsid inhibitor. ab-506 was in a phase 1a/1b clinical trial for the treatment of chronic hepatitis b (chb). as a result of the decision to discontinue further development of ab-506, arbutus no longer expects to initiate a combination study of ab-506 and ab-729 in the second half of 2020.
ABUS Ratings Summary
ABUS Quant Ranking